nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2021-1-138-144nnp-1513Research ArticleCONSENSUS OF EXPERT MEETINGКОНСЕНСУС ЭКСПЕРТНОГО СОВЕЩАНИЯNew possibilities of siponimod therapy in patients with secondary progressive multiple sclerosisНовые возможности терапии у пациентов с вторично-прогрессирующим рассеянным склерозом препаратом сипонимодКасаткинД. С.KasatkinD. S.

150000, Ярославль, ул. Революционная, 5

5, Revolutsionnaya St., Yaroslavl 150000

ХачановаН. В.KhachanovaN. V.

Наталья Валерьевна Хачанова

Москва, 117997, ул. Островитянова, 1

1, Ostrovityanov St., Moscow 117997

voroba.nat@mail.ruАлифироваВ. М.AlifirovaV. M.

634050, Томск, Московский тракт, 2

2, Moskovsky High Road, Tomsk 634050

БойкоА. Н.BoykoA. N.

отдел нейроиммунологииМосква, 117997, ул. Островитянова, 1

1, Ostrovityanov St., Moscow 117997

Department of Neuroimmunology 

БахтияроваК. З.BakhtiyarovaK. Z.

450008, Уфа, ул. Ленина, 3

3; Lenin St., Ufa 450008

ВласовЯ. В.VlasovYa. V.

443099, Самара, ул. Чапаевская, 89

89, Chapaevskaya St., Samara 443099

ДавыдовскаяМ. В.DavydovskayaM. V.

Москва, 117997, ул. Островитянова, 1

143403, Московская обл., Красногорск, ул. Карбышева, 4 литер а

1, Ostrovityanov St., Moscow 117997

 

ЕвдошенкоЕ. П.EvdoshenkoE. P.

Городской центр по лечению рассеянного склероза197110, Санкт-Петербург, пр. Динамо, 3

City Center for Multiple Sclerosis3, Dynamo Pr., Saint Petersburg 197110

СиверцеваС. А.SivertsevaS. A.

625048, Тюмень, ул. Шиллера, 12

12, Schiller St., Tyumen 625048

ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииРоссияYaroslavl State Medical University, Ministry of Health of RussiaRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian FederationФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииРоссияSiberian State Medical University, Ministry of Health of RussiaRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА РоссииРоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center of Brain and Neurotechnologies, Federal Biomedical Agency of RussiaRussian FederationФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава РоссииРоссияBashkir State Medical University, Ministry of Health of RussiaRussian FederationФГБОУ ВО «Самарский государственный медицинский университет» Минздрава РоссииРоссияSamara State Medical University, Ministry of Health of RussiaRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ГБУ МО «Научно-практический центр клинико-экономического анализа Министерства здравоохранения Московской области»РоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Research and Practical Center for Clinical and Economic Analysis, Ministry of Health of the Moscow RegionRussian FederationСПб ГБУЗ «Городская клиническая больница №31»РоссияCity Clinical Hospital Thirty-OneRussian FederationАО «Медико-санитарная часть «Нефтяник», Тюменский областной центр рассеянного склерозаРоссияAO «Neftyanik» Primary Healthcare Unit, Tyumen Regional Center for Multiple SclerosisRussian Federation202117022021131138144Copyright © Kasatkin D.S., Khachanova N.V., Alifirova V.M., Boyko A.N., Bakhtiyarova K.Z., Vlasov Y.V., Davydovskaya M.V., Evdoshenko E.P., Sivertseva S.A., 20212021Касаткин Д.С., Хачанова Н.В., Алифирова В.М., Бойко А.Н., Бахтиярова К.З., Власов Я.В., Давыдовская М.В., Евдошенко Е.П., Сиверцева С.А.Kasatkin D.S., Khachanova N.V., Alifirova V.M., Boyko A.N., Bakhtiyarova K.Z., Vlasov Y.V., Davydovskaya M.V., Evdoshenko E.P., Sivertseva S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1513

The process of neurodegeneration in multiple sclerosis (MS) remains an urgent problem of modern neurology; from the point of view of its therapy, it is especially important to identify this condition during the transition to secondary progression. This paper reflects the opinion of the Council of Leading MS Experts on the early detection of secondary progressive MS and its diagnostic tools, including the use of new online questionnaires. Special attention is paid to the concept of clinical progression verification using the indicator of the confirmed progression of disability and to the prospect for introducing siponimod (Kiendra® ) into clinical practice for the treatment of patients with secondary progressive MS.

Процесс нейродегенерации при рассеянном склерозе (РС) остается актуальной проблемой современной неврологии; особенно важно с точки зрения терапии выявление этого состояния на этапе перехода во вторичное прогрессирование. Данная статья отражает позицию совета ведущих экспертов в области РС в отношении раннего выявления и инструментов диагностики вторично-прогрессирующего РС, в том числе использования новых онлайн-опросников. Особое внимание уделено концепции верификации клинического прогрессирования с использованием показателя подтвержденного прогрессирования инвалидизации, а также перспективе внедрения в клиническую практику препарата сипонимод (Кайендра®) для терапии пациентов с вторично-прогрессирующим РС.

рассеянный склерозвторично-прогрессирующий рассеянный склерознейродегенерациясовет экспертовсипонимодmultiple sclerosissecondary progressive multiple sclerosisneurodegenerationcouncil of expertssiponimodСтатья спонсируется компанией «Новартис».This article has been supported Novartis.ReferencesZiemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24.Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24.Oh J, Alikhani K, Bruno T, et al. Diagnosis and management of secondary-progressive multiple sclerosis: time for change. Neurodegener Dis Manag. 2019 Dec;9(6):301-17. doi: 10.2217/nmt-2019-0024. Epub 2019 Nov 26.Oh J, Alikhani K, Bruno T, et al. Diagnosis and management of secondary-progressive multiple sclerosis: time for change. Neurodegener Dis Manag. 2019 Dec;9(6):301-17. doi: 10.2217/nmt-2019-0024. Epub 2019 Nov 26.Bsteh G, Ehling R, Lutterotti A, et al. Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS One. 2016 Jul 8;11(7):e0158978. doi: 10.1371/journal.pone.0158978Bsteh G, Ehling R, Lutterotti A, et al. Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS One. 2016 Jul 8;11(7):e0158978. doi: 10.1371/journal.pone.0158978Касаткин ДС, Молчанова СС, Спирин НН. Ранняя когнитивная дисфункция как маркер неблагоприятного течения рассеянного склероза: проспективное 12-летнее наблюдение. Неврология, нейропсихиатрия, психосоматика. 2019;11(3):47-51. doi: 10.14412/20742711-2019-3-47-51Kasatkin DS, Molchanova SS, Spirin NN. Early cognitive dysfunction as a marker for the poor course of multiple sclerosis: a prospective 12-year follow-up. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):47-51. doi: 10.14412/2074-27112019-3-47-51 (In Russ.).Amur S, LaVange L, Zineh I, et al. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization. Clin Pharmacol Ther. 2015 Jul;98(1):34-46. doi: 10.1002/cpt.136Amur S, LaVange L, Zineh I, et al. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization. Clin Pharmacol Ther. 2015 Jul;98(1):34-46. doi: 10.1002/cpt.136Ontaneda D, Cohen JA, Amato MP. Clinical outcome measures for progressive MS trials. Mult Scler. 2017 Oct;23(12):1627-35. doi: 10.1177/1352458517729465Ontaneda D, Cohen JA, Amato MP. Clinical outcome measures for progressive MS trials. Mult Scler. 2017 Oct;23(12):1627-35. doi: 10.1177/1352458517729465Motl RW, Cohen JA, Benedict R, et al; Multiple Sclerosis Outcome Assessments Consortium. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):704-10. doi: 10.1177/1352458517690823Motl RW, Cohen JA, Benedict R, et al; Multiple Sclerosis Outcome Assessments Consortium. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):704-10. doi: 10.1177/1352458517690823Feys P, Lamers I, Francis G, et al. Multiple Sclerosis Outcome Assessments Consortium. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):711-20. doi: 10.1177/1352458517690824Feys P, Lamers I, Francis G, et al. Multiple Sclerosis Outcome Assessments Consortium. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):711-20. doi: 10.1177/1352458517690824Learmonth YC, Dlugonski DD, Pilutti LA, et al. The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis. Mult Scler. 2013 Nov;19(13):1784-91. doi: 10.1177/1352458513483890. Epub 2013 Apr 15.Learmonth YC, Dlugonski DD, Pilutti LA, et al. The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis. Mult Scler. 2013 Nov;19(13):1784-91. doi: 10.1177/1352458513483890. Epub 2013 Apr 15.Benedict RH, DeLuca J, Phillips G, et al; Multiple Sclerosis Outcome Assessments Consortium. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):721-33. doi: 10.1177/1352458517690821Benedict RH, DeLuca J, Phillips G, et al; Multiple Sclerosis Outcome Assessments Consortium. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):721-33. doi: 10.1177/1352458517690821Balcer LJ, Raynowska J, Nolan R, et al; Multiple Sclerosis Outcome Assessments Consortium. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):734-47. doi: 10.1177/1352458517690822Balcer LJ, Raynowska J, Nolan R, et al; Multiple Sclerosis Outcome Assessments Consortium. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):734-47. doi: 10.1177/1352458517690822Волков АИ, Попова ЕВ. Новые инструменты для раннего выявления прогрессирования рассеянного склероза. Опросник MSProDiscuss. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(7 вып. 2):43-7. doi: 10.17116/jnevro202012007243Volkov AI, Popova EV. New tools for early detection of multiple sclerosis progression: MSProDiscuss Questionnaire. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(7 Is. 2):43-7. doi: 10.17116/jnevro202012007243 (In Russ.).Ziemssen T, Piani-Meier D, Bennett B, et al. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. J Med Internet Res. 2020;22(2):e16932. doi: 10.2196/16932Ziemssen T, Piani-Meier D, Bennett B, et al. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. J Med Internet Res. 2020;22(2):e16932. doi: 10.2196/16932Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014 Oct;20(12):1654-7. doi: 10.1177/1352458514521517. Epub 2014 Feb 3.Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014 Oct;20(12):1654-7. doi: 10.1177/1352458514521517. Epub 2014 Feb 3.Проект клинических рекомендаций по рассеянному склерозу. Доступно по ссылке: https://www.centrems.com/downloads/Clinical_recommendations_of_the_RS-Project_submitted_to_the_MHRF.pdf (дата обращения 31.12.2020).Draft clinical practice guidelines for multiple sclerosis. Available from: https://www.centrems.com/downloads/Clinical_recommendations_of_the_RS-Project_submitted_to_the_MHRF.pdf (accessed 31.12.2020) (In Russ.).Lorscheider J, Buzzard K, Jokubaitis V, et al; MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.Lorscheider J, Buzzard K, Jokubaitis V, et al; MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.Kappos L, Bar-Or A, Cree BAC, et al; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263-73. doi: 10.1016/S01406736(18)30475-6Kappos L, Bar-Or A, Cree BAC, et al; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263-73. doi: 10.1016/S01406736(18)30475-6Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015 Nov;138(Pt 11):3287-98. doi: 10.1093/brain/awv258. Epub 2015 Sep 10.Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015 Nov;138(Pt 11):3287-98. doi: 10.1093/brain/awv258. Epub 2015 Sep 10.European Medicines agency: Guideline onclinical investigation of medicinal products forthe treatment of Multiple Sclerosis Committeefor Medicinal Products for Human Use. EMA/CHMP/771815/2011, Rev. 2; 2015. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiplesclerosis_en-0.pdfEuropean Medicines agency: Guideline onclinical investigation of medicinal products forthe treatment of Multiple Sclerosis Committeefor Medicinal Products for Human Use. EMA/CHMP/771815/2011, Rev. 2; 2015. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiplesclerosis_en-0.pdfRiester K, Kappos L, Selmaj K, et al. Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials. Mult Scler Relat Disord. 2019 Nov 23;39:101865. doi: 10.1016/j.msard.2019.101865Riester K, Kappos L, Selmaj K, et al. Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials. Mult Scler Relat Disord. 2019 Nov 23;39:101865. doi: 10.1016/j.msard.2019.101865Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020 Sep 1;77(9):1132-40. doi: 10.1001/jamaneurol.2020.1568Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020 Sep 1;77(9):1132-40. doi: 10.1001/jamaneurol.2020.1568Kappos L, Weinshenker B, Pozzilli C, et al; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63(10):1779-87 doi: 10.1212/01.wnl.0000145561.08973.4fKappos L, Weinshenker B, Pozzilli C, et al; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63(10):1779-87 doi: 10.1212/01.wnl.0000145561.08973.4fSamjoo IA, Worthington E, Haltner A, et al. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Curr Med Res Opin. 2020 Jul;36(7):1157-66. doi: 10.1080/03007995.2020.1747999Samjoo IA, Worthington E, Haltner A, et al. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Curr Med Res Opin. 2020 Jul;36(7):1157-66. doi: 10.1080/03007995.2020.1747999Giovannoni G. Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. ECTRIMS Online Library. 09/12/19; 278217; P1015.Giovannoni G. Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. ECTRIMS Online Library. 09/12/19; 278217; P1015.Neuberger EE, Abbass IM, Jones E, Engmann NJ. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis. Neurol Ther. 2020 Nov 26. doi: 10.1007/s40120-020-00224-1Neuberger EE, Abbass IM, Jones E, Engmann NJ. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis. Neurol Ther. 2020 Nov 26. doi: 10.1007/s40120-020-00224-1Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019 May;266(5):1182-93. doi: 10.1007/s00415-01909248-6. Epub 2019 Feb 28.Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019 May;266(5):1182-93. doi: 10.1007/s00415-01909248-6. Epub 2019 Feb 28.Hartung HP, Gonsette R, König N, et al; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 Dec 21-28;360(9350):2018-25. doi: 10.1016/S0140-6736(02)12023-XHartung HP, Gonsette R, König N, et al; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 Dec 21-28;360(9350):2018-25. doi: 10.1016/S0140-6736(02)12023-XMartinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013 May 31;(5):CD002127. doi: 10.1002/14651858.CD002127.pub3Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013 May 31;(5):CD002127. doi: 10.1002/14651858.CD002127.pub3Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010 May 4;74(18):1463-70. doi: 10.1212/WNL.0b013e3181dc1ae0Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010 May 4;74(18):1463-70. doi: 10.1212/WNL.0b013e3181dc1ae0Евдошенко ЕП, Неофидов НА, Бахтиярова КЗ и др. Эффективность и безопасность сипонимода у пациентов с вторичнопрогрессирующим рассеянным склерозом в российской популяции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(10 вып. 2):111-20. doi: 10.17116/jnevro2019119102111Evdoshenko EP, Neofidov NA, Bakhtiyarova KZ, et al. Efficacy and safety of syponimode in patients with secondary progressive multiple sclerosis in the Russian population. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019;119(10 Iss. 2):111-20. doi: 10.17116/jnevro2019119102111 (In Russ.).Инструкция по медицинскому применению препарата Кайендра® . Доступно по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=56d76c7b-756f-4152-847441fe1663c915&t=Instructions for the medical use of Kiendra® . Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=56d76c7b-756f-4152-8474-41fe1663c915&t= (In Russ.).

The authors declare that there are no conflicts of interest present.